Human Genome Epidemiology Literature Finder
Records 1 - 18 (of 18 Records) |
Query Trace: Diarrhea and BRAF[original query] |
---|
Phase II study of irinotecan and cetuximab given every 2 weeks as second-line therapy for advanced colorectal cancer. Clinical colorectal cancer 2012 Mar 11 (1): 53-9. Carneiro Benedito A, Ramanathan Ramesh K, Fakih Marwan G, Krishnamurthi Smitha S, Lembersky Barry C, Stoller Ronald G, Lancaster Stewart L, Pinkerton Richard A, Crandall Theodore L, Schmotzer Amy R, Potter Douglas M, Bahary Nath |
Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research 2012 Jan 18 (2): 555-67. Kirkwood John M, Bastholt Lars, Robert Caroline, Sosman Jeff, Larkin James, Hersey Peter, Middleton Mark, Cantarini Mireille, Zazulina Victoria, Kemsley Karin, Dummer Reinha |
Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2013 Feb 24 (2): 412-9. André T, Blons H, Mabro M, Chibaudel B, Bachet J-B, Tournigand C, Bennamoun M, Artru P, Nguyen S, Ebenezer C, Aissat N, Cayre A, Penault-Llorca F, Laurent-Puig P, de Gramont A, |
Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements. Clinical cancer research : an official journal of the American Association for Cancer Research 2012 Apr 18 (7): 2056-65. Hayes D Neil, Lucas Amy S, Tanvetyanon Tawee, Krzyzanowska Monika K, Chung Christine H, Murphy Barbara A, Gilbert Jill, Mehra Ranee, Moore Dominic T, Sheikh Arif, Hoskins Janelle, Hayward Michele C, Zhao Ni, O'Connor Wendi, Weck Karen E, Cohen Roger B, Cohen Ezra E |
Effect of RAS status on anti-EGFR monoclonal antibodies + 5-FU infusion-based chemotherapy in first-line treatment of metastatic colorectal cancer: A meta-analysis. Meta gene 2016 Sep 9 110-9. Zhou Mingyi, Yu Ping, Hou Kezuo, Fu Lingyu, Chen Ying, Qu Jinglei, Qu Xiujuan, Liu Yunpeng, Zhang Jingdo |
Phase II study of panitumumab combined with capecitabine and oxaliplatin as first-line treatment in metastatic colorectal cancer patients: clinical results including extended tumor genotyping. Medical oncology (Northwood, London, England) 2018 May 35 (7): 101. Papaxoinis George, Kotoula Vassiliki, Giannoulatou Eleni, Koliou Georgia-Angeliki, Karavasilis Vasilios, Lakis Sotirios, Koureas Andreas, Bobos Mattheos, Chalaralambous Elpida, Daskalaki Emily, Chatzopoulos Kyriakos, Tsironis George, Pazarli Elisavet, Chrisafi Sofia, Samantas Epaminontas, Kaklamanos Ioannis G, Varthalitis Ioannis, Konstantara Athina, Syrigos Konstantinos N, Pentheroudakis George, Pectasides Dimitrios, Fountzilas Geor |
Phase II trial of biweekly cetuximab and irinotecan as third-line therapy for pretreated KRAS exon 2 wild-type colorectal cancer. Cancer science 2018 Jun . Osumi Hiroki, Shinozaki Eiji, Mashima Tetsuo, Wakatsuki Takeru, Suenaga Mitsukuni, Ichimura Takashi, Ogura Mariko, Ota Yumiko, Nakayama Izuma, Takahari Daisuke, Chin Keisho, Miki Yoshio, Yamaguchi Kens |
First-in-Human Phase I Study of AC0010, a Mutant-Selective EGFR Inhibitor in Non-Small Cell Lung Cancer: Safety, Efficacy, and Potential Mechanism of Resistance. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2018 4 13 (7): 968-977. Ma Yuxiang, Zheng Xin, Zhao Hongyun, Fang Wenfeng, Zhang Yang, Ge Jieying, Wang Lu, Wang Weicong, Jiang Ji, Chuai Shaokun, Zhang Zhou, Xu Wanhong, Xu Xiao, Hu Pei, Zhang |
Italian survey on cetuximab-based therapy of elderly patients with metastatic colorectal cancer. Cancer chemotherapy and pharmacology 2019 9 84 (5): 1089-1096. Rosati Gerardo, Addeo Raffaele, Aprile Giuseppe, Avallone Antonio, Bilancia Domenico, Brugnatelli Silvia, Buccafusca Gabriella, Carlomagno Chiara, Cordio Stefano, Delfanti Sara, Dell'Aquila Emanuela, Di Bisceglie Maurizio, Di Donato Samantha, Di Stasi Antonio, Germano Domenico, Giuliani Francesco, Granetto Cristina, Latiano Tiziana Pia, Leo Silvana, Tralongo Paolo, Stroppolo Maria Elena, Venturini Filippo, Bianco Salvato |
Phase I Trial of Trametinib with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2020 Apr . Wu Christina, Williams Terence M, Robb Ryan, Webb Amy, Wei Lai, Chen Wei, Mikhail Sameh, Ciombor Kristen K, Cardin Dana B, Timmers Cynthia, Krishna Somashekar G, Arnold Mark, Harzman Alan, Abdel-Misih Sherif, Roychowdhury Sameek, Bekaii-Saab Tanios, Wuthrick Ev |
Cetuximab plus irinotecan administered biweekly with reduced infusion time to heavily pretreated patients with metastatic colorectal cancer and related RAS and BRAF mutation status. International journal of cancer 2020 12 . Jensen Benny Vittrup, Schou Jakob V, Yilmaz Mette, Johannesen Helle H, Skougaard Kristin, Linnemann Dorte, Hogdall Estrid V, Larsen Finn O, Johansen Julia S, Pfeiffer Per, Nielsen Dorte |
Phase II Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Metastatic Colorectal Cancer. Clinical colorectal cancer 2021 Jul . Alshammari Kanan, Aung Kyaw L, Zhang Tong, Razak Albiruni R A, Serra Stefano, Stockley Tracy, Wang Lisa, Nguyen Jessica, Spreafico Anna, Hansen Aaron R, Zwir Dave, Siu Lillian L, Bedard Philippe |
Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial. JAMA oncology 2021 Aug . Martinelli Erika, Martini Giulia, Famiglietti Vincenzo, Troiani Teresa, Napolitano Stefania, Pietrantonio Filippo, Ciardiello Davide, Terminiello Marinella, Borrelli Carola, Vitiello Pietro Paolo, De Braud Filippo, Morano Federica, Avallone Antonio, Normanno Nicola, Nappi Anna, Maiello Evaristo, Latiano Tiziana, Falcone Alfredo, Cremolini Chiara, Rossini Daniele, Santabarbara Giuseppe, Pinto Carmine, Santini Daniele, Cardone Claudia, Zanaletti Nicoletta, Di Liello Alessandra, Renato Daniela, Esposito Lucia, Marrone Francesca, Ciardiello Fortuna |
Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience. ESMO open 2022 6 7 (3): 100506. Boccaccino A, Borelli B, Intini R, Antista M, Bensi M, Rossini D, Passardi A, Tamberi S, Giampieri R, Antonuzzo L, Noto L, Roviello G, Zichi C, Salati M, Puccini A, Noto C, Parisi A, Rihawi K, Persano M, Crespi V, Libertini M, Giordano M, Moretto R, Lonardi S, Cremolini |
Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO precision oncology 2022 11 6 e2200191. Klute Kelsey A, Rothe Michael, Garrett-Mayer Elizabeth, Mangat Pam K, Nazemzadeh Reza, Yost Kathleen J, Duvivier Herbert L, Ahn Eugene R, Cannon Timothy L, Alese Olatunji B, Krauss John C, Thota Ramya, Calfa Carmen J, Denlinger Crystal S, O'Lone Raegan, Halabi Susan, Grantham Gina N, Schilsky Richard |
A single-center retrospective analysis of the efficacy and safety of a modified regimen of irinotecan plus S-1 (IRIS) with molecular targeting agents as second-line chemotherapy in Japanese patients with recurrent or nonresectable colorectal cancer. Journal of gastrointestinal oncology 2023 5 14 (2): 663-675. Shigeo Higami, Masaya Mukai, Daiki Yokoyama, Syuji Uda, Rin Abe, Nana Mamuro, Kyoko Kishima, Sayuri Hasegawa, Takayuki Tajima, Eiji Nomura, Hiroyasu Makuuc |
Final analysis of a post-marketing surveillance study of dabrafenib and trametinib combination therapy in Japanese patients with unresectable malignant melanoma with BRAF V600 mutation. The Journal of dermatology 2023 3 . Kaizuka Tomoaki, Kurihara Ryohei, Harumiya Miki, Kimura Takayuki, Ushida Nao |
Triplet chemotherapy plus cetuximab as first-line treatment in extended RAS wild-type metastatic colorectal cancer patients. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2024 1 . Emmanuelle Samalin, Thibault Mazard, Eric Assenat, Magali Rouyer, Christelle de la Fouchardière, Rosine Guimbaud, Denis Smith, Fabienne Portales, Marc Ychou, Antoine Adenis, Catherine Fiess, Evelyne Lopez-Crapez, Simon Thezen |
- Page last reviewed:Feb 1, 2024
- Page last updated:Mar 18, 2024
- Content source: